The University of Chicago Medicine Comprehensive Cancer Center, Chicago
UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
UChicago Medicine Orland Park, Orland Park

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT05868226

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Northwestern Medicine Chicago Proton Center, Warrenville

În curs de recrutareFaza 2

Vârste de 50 ani și peste · Femei · Actualizat 29 sept. 2026 · NCT01766297

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

The University of Chicago Medicine Comprehensive Cancer Center, Chicago

În curs de recrutare

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07553234

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Rush University Medical Center ( Site 0079), Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06312176

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

City of Hope Chicago, Zion

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Peoria
Clinical Trial Site, Urbana

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 23 sept. 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Northwestern University, Chicago

În curs de recrutare

Vârste de 18 ani și peste · Toate sexele · Actualizat 23 sept. 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

City of Hope, Chicago, Chicago
Northwestern Memorial Hospital, Chicago
University of Illinois at Chicago, Chicago
și încă 3

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07174336

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

University of Chicago, Chicago

În curs de recrutareVoluntari sănătoși bineveniți

Vârste de la 30 la 74 · Femei · Actualizat 21 sept. 2026 · NCT02620852

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Cancer Care Specialists, Decatur
Cancer Care Specialists of Illinois, O'Fallon
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

City of Hope, Chicago, Zion

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT07109726

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University of Illinois Hospital & Health Sciences System, Chicago

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Illinois Cancer Specialists, Arlington Heights
Northwestern Memorial Hospital, Chicago
RUSH MD Anderson Cancer Center, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 15 sept. 2026 · NCT06492616

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Orchard Healthcare Research Inc., Skokie

În curs de recrutareStudiu observațional

Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT05935384

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope® Cancer Center Chicago, Zion

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT03424005

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Orchard Healthcare Research Inc. ( Site 0006), Skokie

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT06797635

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

University of Illinois Cancer Center, Chicago
University of Chicago Medicine, Chicago
City of Hope - Chicago, Zion

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 10 sept. 2026 · NCT06293898

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Chicago, Chicago

În curs de recrutareFaza 1

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT06253871

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Carle Cancer Center, Urbana

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT05386108

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

NorthShore University Health System - Evanston Hospital, Evanston
NorthShore University HealthSystem - Evanston Hospital, Evanston
Duly Health and Care, Lisle
și încă 2

În curs de recrutareFaza 1

Vârste de la 18 la 55 · Femei · Actualizat 9 sept. 2026 · NCT07310420

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Evanston

În curs de recrutareFaza 3

Vârste de la 18 la 130 · Toate sexele · Actualizat 8 sept. 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

City of Hope® Cancer Center Chicago, Zion

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT07100106

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Northwestern University, Chicago

În curs de recrutareFaza 1/2

Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT05315700

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Northwestern University, Chicago
Rush University Medical Center, Chicago
University of Chicago, Chicago

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT06062498

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Rush University Medical Center, Chicago
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Southern Illinois Hospital Services, Carbondale
Cancer Care Specialist of Illinois, O'Fallon

În curs de recrutareStudiu observațional

Vârste de la 18 la 99 · Toate sexele · Actualizat 3 sept. 2026 · NCT07211178

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

University of Illinois Cancer Center, Chicago

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT04886531

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Cancer Care Specialists of Central Illinois, O'Fallon
Springfield Clinic, Springfield
Carle Cancer Center, Urbana
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

OSF Saint Anthony's Health Center, Alton
Advocate Outpatient Center - Aurora, Aurora
Advocate Good Shepherd Hospital, Barrington
și încă 83

În curs de recrutareFaza 3

Vârste de la 18 la 60 · Femei · Actualizat 2 sept. 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Northwestern University, Chicago
Southern Illinois University-Simmons, Springfield
Carle Foundation Cancer Institute-Urbana, Urbana

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 2 sept. 2026 · NCT06072612

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

University Of Chicago Medicine Comprehensive Cancer Center, Chicago

În curs de recrutareVoluntari sănătoși bineveniți

Vârste de 25 ani și peste · Femei · Actualizat 1 sept. 2026 · NCT03729115

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

University of Chicago Medical Center, Chicago

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 26 aug. 2026 · NCT06533826

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 aug. 2026 · NCT06764940

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

University of Illinois, Chicago

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 21 aug. 2026 · NCT06441890

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.